查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
利用真实世界证据 (RWE) 协助製药产业取得策略优势
市场调查报告书
商品编码
1776188

利用真实世界证据 (RWE) 协助製药产业取得策略优势

Harnessing Real-World Evidence for Strategic Advantage in Pharma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入探讨了真实世界证据 (RWE) 在药物生命週期中的策略整合，重点关注其从补充资料来源到决策关键推动因素的演变。报告探讨了监管机构对 RWE 日益增长的接受度、其在卫生技术评估中的作用以及其对市场准入和报销策略的影响。报告还探讨了上市后监管的课题、对建立紧密结合的数据生态系统的需求，以及人工智慧 (AI) 在 RWE 生成方面的变革潜力。建立强大的 RWE 能力并将证据与付款人需求相结合，可以提供有助于推动策略成果的洞察。

关键问题解答

  • 1.药厂如何利用真实世界证据 (RWE) 协助取得策略优势？
  • 2.RWE 在製药业中的战略重要性是什么？
  • 3.如何在监理申报中有效利用 RWE？
  • 4.RWE 如何影响健康科技评估 (HTIA)？
  • 5.RWE 如何增强市场进入与报销策略？
  • 6.RWE 在上市后监理中扮演什么角色？
  • 7.建构强大 RWE 能力的最佳实践是什么？
  • 8.分析方法的进步如何改变 RWE 的生成？
  • 9.企业必须克服哪些课题才能将 RWE 纳入製药策略？
  • 10.企业如何将 RWE 与付款人需求结合，以打开市场准入的大门？

主要企业

  • UCB
  • LEO Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Flatiron Health
  • Apple
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Aetion

部分参加专家名单

  • 比利时优时比（UCB）RWE免疫学负责人
  • 全球製药公司临床策略与证据生成副总监
  • 丹麦利奥製药（LEO Pharma）全球策略、证据与传播负责人
  • 德国阿斯特捷利康（AstraZeneca）医疗与法规事务副总裁
  • 德国勃林格殷格翰（Boehringer Ingelheim）全球临床营运总监
  • 英国优时比（UCB）副总裁、全球RWE与数位科学负责人

方法论：

檔案报告是基于独立而简洁的分析，这些分析源自于专有的产业研究以及与产业思想领袖的深入访谈。这些报告深入分析了製药企业高阶主管需要了解的关键趋势和市场发展，以应对未来的机会和课题。每份报告的重点都基于对二手文献的回顾和已发现的知识差距。基于这些初步研究，我们制定了基于证据的讨论指南，并结合专家意见，以确保研究能够解答最重要的问题。此外，我们采用严格的筛选标准，以确保受访者拥有相应的经验、知识和发言资格。

我们的报告有何独特之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助我们的客户掌握新兴趋势并有效解决复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家专访和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个活跃疾病领域，包含 KOL 洞察和定量医生调查等医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。

简介目录

This report delves into the strategic integration of real-world evidence (RWE) across the pharmaceutical lifecycle, highlighting its evolution from a supplementary data source to a critical driver of decision-making. It examines the growing regulatory acceptance of RWE, its role in health technology assessments and its impact on market access and reimbursement strategies. The report also addresses the challenges of post-marketing surveillance, the need for cohesive data ecosystems and the transformative potential of AI in RWE generation. Gain insights into building robust RWE capabilities and aligning evidence with payer needs to enhance strategic outcomes.

Key Questions Answered:

  • 1. How can pharmaceutical companies leverage real-world evidence (RWE) for strategic advantage?
  • 2. What is the strategic importance of RWE in the pharmaceutical industry?
  • 3. How can RWE be effectively used in regulatory submissions?
  • 4. In what ways does RWE influence health technology assessments?
  • 5. How does RWE enhance market access and reimbursement strategies?
  • 6. What role does RWE play in post-marketing surveillance?
  • 7. What are the best practices for building robust RWE capabilities?
  • 8. How are advances in analytical methods transforming RWE generation?
  • 9. What challenges must be overcome to integrate RWE into pharma strategy?
  • 10. How can companies align RWE with payer needs to unlock market access?

Key Companies:

  • UCB
  • LEO Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Flatiron Health
  • Apple
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Novartis
  • Aetion

Partial List of Participating Experts:

  • Head of RWE Immunology, UCB, Belgium
  • Associate Director, Clinical Strategy and Evidence Generation, global pharma company
  • Head of Global Strategic Evidence and Communications, LEO Pharma, Denmark
  • VP Medical & Regulatory, AstraZeneca, Germany
  • Global Head Clinical Practice, Boehringer Ingelheim, Germany
  • Vice President, Head of Global RWE and Digital Sciences, UCB, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.